Comparative Pharmacology
Head-to-head clinical analysis: BALZIVA 28 versus QUARTETTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BALZIVA 28 versus QUARTETTE.
BALZIVA-28 vs QUARTETTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BALZIVA-28 is a combination estrogen-progestin oral contraceptive. Ethinyl estradiol provides estrogenic activity, while levonorgestrel acts as a progestin, primarily suppressing gonadotropin (FSH and LH) release from the pituitary, inhibiting ovulation, and causing changes in cervical mucus and endometrium to reduce sperm penetration and implantation.
Combination oral contraceptive containing drospirenone, ethinyl estradiol, levomefolate calcium, and metformin. Drospirenone is a progestin with antimineralocorticoid and antiandrogenic activity. Ethinyl estradiol is an estrogen. Levomefolate calcium is a folate supplement. Metformin is a biguanide that decreases hepatic glucose production and improves insulin sensitivity.
One tablet (0.5 mg levonorgestrel and 0.1 mg ethinyl estradiol) orally once daily for 28 days, starting on the first day of menstrual cycle.
3 mg orally once daily for 21 days followed by 7 days of placebo.
None Documented
None Documented
2.5 hours; clinically relevant for dosing interval in renal impairment
Terminal elimination half-life is 12-14 hours; clinically this supports once-daily dosing with steady state achieved within 2-3 days.
Renal: 50-60% as unchanged drug; fecal: 30-40% as metabolites; biliary: <5%
Renal excretion accounts for 55% (primarily as unchanged drug), biliary/fecal excretion 35%, and the remainder undergoes metabolic clearance.
Category C
Category C
Oral Contraceptive
Oral Contraceptive